Spiro | 62778-57-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 茚满类
• 英文名称: Spiro
• 英文别名: 1,3-Dihydrospiro[indene-2,2'-pyrrolidine]；spiro[1,3-dihydroindene-2,2'-pyrrolidine]
• CAS: 62778-57-8
• 化学式: C₁₂H₁₅N
• 分子量: 173.258
• InChiKey: WFZPZHXVHKEVAZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  13
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  1

文献信息

• [EN] 1-ACYL-PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS<br/>[FR] DERIVES DE 1-ACYL-PYRROLIDINE DESTINES AU TRAITEMENT D'INFECTIONS VIRALES
  申请人：GLAXO GROUP LTD

  公开号：WO2004037818A1

  公开（公告）日：2004-05-06

  Anti-viral agents of Formula (I) wherein: A represents hydroxy; D represents aryl or heteroaryl; E represents hydrogen, C1-6alkyl, aryl, heteroaryl or heterocyclyl; G represents hydrogen or optionally substituted C1-6alkyl; J represents C1-6alkyl, heterocyclylalkyl, arylalkyl or heteroarylalkyl;and salts, solvates and esters thereof; provided that when A is esterified to form -OR where R is selected from straight or branched chain alkyl, aralkyl, aryloxyalkyl, or aryl, then R is other than tert-butyl;processes for their preparation, pharmaceutical compositions comprising them, and methods of using them in HCV treatment are provided.

  化学式（I）的抗病毒剂其中：A代表羟基；D代表芳基或杂芳基；E代表氢、C1-6烷基、芳基、杂芳基或杂环烷基；G代表氢或可选择地取代的C1-6烷基；J代表C1-6烷基、杂环烷基烷基、芳基烷基或杂芳基烷基；及其盐、溶剂合物和酯；提供它们的制备方法、包含它们的药物组合物以及在丙型肝炎病毒治疗中使用它们的方法。
• [EN] ACYL DIHYDRO PYRROLE DERIVATIVES AS HCV INHIBITORS<br/>[FR] DERIVES ACYL-DIHYDRO-PYRROLE UTILISES EN TANT QU'INHIBITEURS DU VHC
  申请人：GLAXO GROUP LTD

  公开号：WO2005103045A1

  公开（公告）日：2005-11-03

  Novel anti-viral agents of Formula (I) in which: A represents hydroxy; D represents aryl or heteroaryl; E represents hydrogen, C1-6alkyl, aryl, heteroaryl or heterocyclyl; G represents hydrogen or C1-6alkyl optionally substituted by one or more substituents selected from halo, OR1, SR1, C(O)NR2R3, CO2H, C(O)R4, CO2R4, NR2R3, NHC(O)R4, NHCO2R4, NHC(O)NR5R6, SO2NR5R6, SO2R4, nitro, cyano, aryl, heteroaryl and heterocyclyl; R1 represents hydrogen, C1-6alkyl, arylalkyl, or heteroarylalkyl; R2 and R3 are independently selected from hydrogen, C1-6alkyl, aryl and heteroaryl; or R2 and R3 together with the nitrogen atom to which they are attached form a 5 or 6 membered saturated cyclic group; R4 is selected from the group consisting of C1-6alkyl, aryl, heteroaryl, arylalkyl, and heteroarylalkyl; R5 and R6 are independently selected from the group consisting of hydrogen, C1-6alkyl, aryl, heteroaryl, arylalkyl, and heteroarylalkyl; or R5 and R6 together with the nitrogen atom to which they are attached form a 5 or 6 membered saturated cyclic group; and J represents C1-6alkyl, heterocyclylalkyl, arylalkyl or heteroarylalkyl; and salts, solvates and esters thereof; provided that when A is esterified to form -OR where R is selected from straight or branched chain alkyl, aralkyl, aryloxyalkyl, or aryl, then R is other than tert-butyl; processes for their preparation, pharmaceutical compositions comprising them, and methods of using them in HCV treatment are provided.

  公式（I）中的新型抗病毒剂：A代表羟基；D代表芳基或杂芳基；E代表氢、C1-6烷基、芳基、杂芳基或杂环烷基；G代表氢或C1-6烷基，可选择地被来自卤素、OR1、SR1、C(O)NR2R3、CO2H、C(O)R4、CO2R4、NR2R3、NHC(O)R4、NHCO2R4、NHC(O)NR5R6、SO2NR5R6、SO2R4、硝基、氰基、芳基、杂芳基和杂环烷基的一个或多个取代基取代；R1代表氢、C1-6烷基、芳基烷基或杂芳基烷基；R2和R3独立地选自氢、C1-6烷基、芳基和杂芳基；或R2和R3与它们连接的氮原子一起形成5或6个成员饱和环；R4从由C1-6烷基、芳基、杂芳基、芳基烷基和杂芳基烷基组成的群体中选择；R5和R6独立地选自氢、C1-6烷基、芳基、杂芳基、芳基烷基和杂芳基烷基的群体；或R5和R6与它们连接的氮原子一起形成5或6个成员饱和环；J代表C1-6烷基、杂环烷基烷基、芳基烷基或杂芳基烷基；及其盐、溶剂合物和酯；但是当A酯化形成-OR（其中R从直链或支链烷基、芳基烷基、芳基氧烷基或芳基中选择）时，则R不是叔丁基；提供了它们的制备方法、包括它们的药物组合物以及在HCV治疗中使用它们的方法。
• 1-Acyl-pyrrolidine derivatives for the treatment of viral infections
  申请人：Haigh David

  公开号：US20060258720A1

  公开（公告）日：2006-11-16

  Anti-viral agents of Formula (I) wherein: A represents hydroxy; D represents aryl or heteroaryl; E represents hydrogen, C 1-6 alkyl, aryl, heteroaryl or heterocyclyl; G represents hydrogen or optionally substituted C 1-6 alkyl; J represents C 1-6 alkyl, heterocyclylalkyl, arylalkyl or heteroarylalkyl; and salts, solvates and esters thereof; provided that when A is esterified to form —OR where R is selected from straight or branched chain alkyl, aralkyl, aryloxyalkyl, or aryl, then R is other than tert-butyl; processes for their preparation, pharmaceutical compositions comprising them, and methods of using them in HCV treatment are provided.

  公式（I）的抗病毒剂，其中： A代表羟基； D代表芳基或杂芳基； E代表氢、C1-6烷基、芳基、杂芳基或杂环基； G代表氢或可选择取代的C1-6烷基； J代表C1-6烷基、杂环基烷基、芳基烷基或杂芳基烷基； 以及其盐、溶剂化合物和酯；但当A被酯化形成-OR时，其中R为直链或支链烷基、芳基烷基、芳氧基烷基或芳基，则R不是叔丁基；提供了其制备方法、包括它们的制药组合物以及在HCV治疗中使用它们的方法。
• [EN] PYRROLOPYRIDAZINE COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF<br/>[FR] COMPOSÉ DE PYRROLOPYRIDAZINE, SON PROCÉDÉ DE PRÉPARATION ET SON UTILISATION<br/>[ZH] 一种吡咯并哒嗪类化合物及其制备方法和用途
  申请人：HANGZHOU ZHONGMEIHUADONG PHARMACEUTICAL CO LTD

  公开号：WO2022166920A1

  公开（公告）日：2022-08-11

  涉及式(I)所示的吡咯并哒嗪类化合物或其药学上可接受的盐，还涉及所述化合物的药物制剂、药物组合物及其应用，所述化合物可用于制备治疗或者预防由HPK1介导的相关疾病。
• [EN] PYRROLOPYRIDINONE COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF<br/>[FR] COMPOSÉ DE PYRROLOPYRIDINONE, SON PROCÉDÉ DE PRÉPARATION ET SON UTILISATION<br/>[ZH] 吡咯并吡啶酮类化合物及其制备方法和用途
  申请人：HANGZHOU ZHONGMEIHUADONG PHARMACEUTICAL CO LTD

  公开号：WO2022258044A1

  公开（公告）日：2022-12-15

  提供式(I)所示的吡咯并吡啶酮类化合物或其药学上可接受的盐，所述化合物的药物制剂、药物组合物及其应用，所述化合物可用于制备治疗或者预防由MAP4K1介导的相关疾病。